Crossject
Develops emergency medications delivered via a needle-free auto-injector platform.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
Description
Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-01 07:30 |
CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liqu…
|
French | 105.6 KB | ||
| 2025-06-24 19:00 |
CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 mil…
|
French | 213.9 KB | ||
| 2025-06-24 19:00 |
CROSSJECT announces a successful capital increase of €5.7 million following ful…
|
English | 206.2 KB | ||
| 2025-06-11 07:30 |
CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les…
|
French | 108.9 KB | ||
| 2025-06-11 07:30 |
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epi…
|
English | 110.5 KB | ||
| 2025-06-06 17:45 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 152.9 KB | ||
| 2025-06-04 20:21 |
Lancement d’une augmentation de capital avec maintien du droit préférentiel de …
|
French | 292.3 KB | ||
| 2025-06-04 20:21 |
Launch of a capital increase with preferential subscription rights for nearly …
|
English | 216.7 KB | ||
| 2025-06-03 07:30 |
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat …
|
French | 100.9 KB | ||
| 2025-06-03 07:30 |
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommenda…
|
English | 100.8 KB | ||
| 2025-05-27 07:30 |
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘…
|
English | 111.6 KB | ||
| 2025-05-27 07:30 |
CROSSJECT met en place un nouveau module de fabrication pour augmenter la polyv…
|
French | 108.8 KB | ||
| 2025-05-20 07:30 |
CROSSJECT prépare le lancement d’une augmentation de capital avec maintien du d…
|
French | 168.0 KB | ||
| 2025-05-20 07:30 |
CROSSJECT prepares for the launch of a capital increase with preferential subs…
|
English | 275.8 KB | ||
| 2025-05-15 07:30 |
L'auto-injecteur sans aiguille ZENEO® de CROSSJECT est conforme aux profondeurs…
|
French | 147.5 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crossject
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
Peer Companies
